This page shows the latest tirzepatide news and features for those working in and with pharma, biotech and healthcare.
The company has delivered 17 new medicines over the course of the last eight years, including tirzepatide, which received US Food and Drug Administration (FDA) approval as Mounjaro, for the treatment
The second is a new drug application (NDA) to the FDA and a marketing authorisation application to the European Medicines Agency (EMA) for tirzepatide for the treatment of adults with type ... through 2030, bolstered by multiple pipeline readouts of its
Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021. ... Tirzepatide is an investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
The company may face new competition in the type 2 diabetes area soon, as a regulatory filing for Eli Lilly’s investigational GIP and GLP-1 receptor agonist tirzepatide looms. ... Also at ADA, Lilly revealed that all doses of tirzepatide tested in a
Among these is tirzepatide, which recently yielded positive results in a head-to-head trial against Novo Nordisk’s semaglutide in type 2 diabetes. ... Tirzepatide demonstrated superiority compared to semaglutide in all doses tested, with the highest
Tirzepatide demonstrated superiority compared to semaglutide in all doses tested, with the highest dose – 15mg – reducing A1C by 2.46% and body weight by 13.1%. ... Tirzepatide is Lilly’s investigational once-weekly dual glucose-dependent
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...